A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD).
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Gevokizumab (Primary)
- Indications Behcet's syndrome; Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- 30 Dec 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 20 Jul 2011 New trial record